<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) has been reported to be strongly associated with Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The fact that EBV is generally present in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells but rarely found in healthy cells represents an opportunity for targeted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>One approach is to activate the lytic replication cycle of the latent EBV </plain></SENT>
<SENT sid="3" pm="."><plain>Nuclear factor (NF)-κB is thought to play an essential role in EBV lytic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Elevated NF-κB levels inhibit EBV lytic replication </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="7939">Parthenolide</z:chebi> (PN) is a <z:chebi fb="0" ids="37667">sesquiterpene lactone</z:chebi> found in medicinal plants, particularly in feverfew (Tanacetum parthenium) </plain></SENT>
<SENT sid="6" pm="."><plain>The aim of the present study was to analyze the effect of PN on the survival of Raji EBV-positive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Raji cells were treated with 0, 4 or 6 µmol/l PN for 48 h </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="53233">MTT</z:chebi> assay and western blot analysis were performed to evaluate the findings </plain></SENT>
<SENT sid="9" pm="."><plain>Results showd that PN suppressed the growth of the EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell line, Raji, and activated the transcription of BZLF1 and BRLF1 by inhibiting NF-κB activity </plain></SENT>
<SENT sid="10" pm="."><plain>Most notably, when PN was used in combination with <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> (GCV), the cytotoxic effect of PN was amplified </plain></SENT>
<SENT sid="11" pm="."><plain>These data suggest that the induction of lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> with PN in combination with GCV may be a <z:mp ids='MP_0001799'>viral</z:mp>‑targeted therapy for EBV-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>